WSWen Shen

Wen Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wen Shen has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vascular endothelial growth factor-A/vascular endothelial growth factor2 signaling in spinal neurons contributes to bone cancer pain

    by Li-Jun Fan, Hou-Ming Kan, Xue-Tai Chen, Yuan-Yuan Sun, Li-Ping Chen, Wen Shen

    Tumor metastasis to bone is often accompanied by a severe pain syndrome (cancer-induced bone pain, CIBP) that is frequently unresponsive to analgesics, which markedly reduces patient quality of life and cancer treatment tolerance in patients. Prolonged pain can induce hypersensitivity via spinal plasticity, and several recent studies have implicated the involvement of vascular endothelial growth factor-A (VEGF-A) signaling in this process. Here, we speculated that CIBP is associated with VEGF-A/VEGFR2 signaling in the spinal cord. A mouse model of CIBP was established by intramedullary injection of Lewis lung carcinoma (LLC) cells in the mouse femur. Pain sensitization and potential amelioration via VEGF-A/VEGFR2 blockade were measured using paw withdrawal threshold to mechanical stimulation and paw withdrawal latency to thermal. Spinal VEGF-A/VEGFR2 signaling was blocked by intrathecal injection of the VEGF-A antibody or the specific VEGFR2 inhibitor ZM323881. Changes in the expression levels of VEGF-A, VEGFR2, and other pain-related signaling factors were measured using western blotting and immunofluorescence staining. Mice after LLC injection demonstrated mechanical allodynia and thermal hyperalgesia, both of which were suppressed via anti-VEGF-A antibody or ZM323881. Conversely, the intrathecal injection of exogenous VEGF-A was sufficient to cause pain hypersensitivity in naïve mice via the VEGFR2-mediated activation of protein kinase C. Moreover, the spinal blockade of VEGF-A or VEGFR2 also suppressed N-methyl-D-aspartate receptor (NMDAR) activation and downstream Ca2+-dependent signaling. Thus, spinal VEGF-A/VEGFR2/NMDAR signaling pathways may be critical mediators of CIBP.


  • Traditional Chinese medicine for breast cancer: A scoping review of systematic reviews

    by Chunli Lu, Nicola Robinson, Jianping Liu, Wen Shen, Xinyan Jin, Hongmei Zhou


  • Open Access

    Application of Zizao Yangrong Granules for Treating Targeted Drugs–Related Skin Xerosis: A Randomized Double-Blinded Controlled Study

    by Yan Mei Peng, Hua Duan, Jingyi Zhang, Chenyao Sun, Xu Zhang, Wen Shen, Shuyue Zheng, Kexin Tan, Xuejiao Jiang, Jia Li, et al.

    Background: Dermatologic toxicities are the most common side effects associated with the targeted drugs epidermal growth factor receptor inhibitors (EGFRIs), in which xerosis commonly complicated by pruritus severely disturbs the quality of life. The study has observed the curative effect of Zizao Yangrong granules (ZYG) from Chishui Xuanzhu in the treatment of EGFRIs-related xerosis and pruritus, as well as evaluating the safety of the prescription. Methods: Patients (n = 68) who had xerosis after using EGFRIs were enrolled and then randomly divided into the treatment group and control group, respectively, receiving ZYG and placebo granules combined with vitamin E ointment. The intervention lasted 4 weeks. Changes in xerosis and pruritus were observed, and blood routine examination as well as liver and kidney function are observed as safety indexes. The water content of skin and qualify of life were observed. Results: A total of 66 out of 68 patients finished the study with 34 patients in each group. The effective rates of xerosis among the treatment group and control group were 84.8% and 69.7% after 2 weeks’ treatment (P < .05), while they were 84.8% and 75.8% after 4 weeks’ treatment (P < .05). The patients in the experimental group had better quality of life than that in the control group (P = .045). Conclusion: ZYG can effectively improve the skin dryness associated with EGFRIs, and significantly improve the quality of life of patients with good safety; however, larger randomized controlled trials are needed to verify these findings.


  • Open Access

    Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report

    by Hua Duan, Yanmei Peng, Huijuan Cui, Yuqin Qiu, Qiang Li, Jingyi Zhang, Wen Shen, Chenyao Sun, Chufan Luo

    Epidermal growth factor receptor-tyrosine kinase inhibitors have improved progression-free survival and overall survival in non-small-cell lung cancer (NSCLC) patients with sensitive mutations. However, response of uncommon mutation to epidermal growth factor receptor-tyrosine kinase inhibitors is still unclear. S768I is one of the uncommon mutations. A female patient with advanced NSCLC with a single S768I mutation achieved effectiveness from afatinib after showing no response to gefitinib. The patient had progression-free survival after taking afatinib for 6 months, and her follow-up is continuing. It suggests that afatinib may be a more effective treatment for NSCLC patients with a single S768I mutation, compared to first-generation tyrosine kinase inhibitors.


  • [The assessment of right ventricular function in patients with pulmonary arterial hypertension with cardiac magnetic resonance imaging: a Meta-analysis].

    by Cui Qian, Ge Xihong, Yu Jing, Gao Guangfeng, Shen Wen

    To explore the clinical value of cardiac magnetic resonance imaging (CMRI) in assessment of right ventricular function in patients with pulmonary arterial hypertension (PAH). The PubMed/MEDLINE, Wanfang data, CNKI (from January 2001 to April 2015) were searched. The search terms were pulmonary arterial hypertension, right ventricular function, and cardiac magnetic resonance imaging. An inclusion criterion was the patients suffering from PAH, and the healthy volunteers were served as controls. The study was designed as randomized controlled trial. All the subjects investigated had received CMRI. The end of the trial included right ventricular end diastolic volume (RVEDV), right ventricular end systolic volume (RVESV) and right ventricular ejection fraction (RVEF). Meta analysis was conducted by RevMan 5.0 software provided by Cochrane Collaboration, and the publication bias was analyzed by the funnel plot analysis. Five papers involving 381 patients met the criteria. It was showed by Meta-analysis that compared with healthy control group, RVEDV was increase in PAH group [weighted mean difference (WMD) = 33.96, 95% confidence interval (95% CI) = 20.80-47.12, P < 0.00001], RVESV was increased (WMD = 41.91, 95% CI = 29.63-54.19, P < 0.00001), and RVEF was decrease (WMD = -20.09, 95% CI = -22.65 to -17.52, P < 0.00001). CMRI can be used to evaluate the right ventricular function of patients with PAH, and it has important significance in the evaluation of right ventricular function in patients with PAH.